HROW241115P35000
- 1.28
- 0.000.00%
Harrow Newsroom
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Raises Target Price to $73
Harrow Health: Promising Growth Trajectory and Compelling Investment Opportunity
B. Riley Adjusts Price Target on Harrow to $73 From $50, Maintains Buy Rating
Express News | Harrow Inc - FDA Agrees to Melt-300 Phase 3 Special Protocol Assessment
Express News | Harrow Inc - Topline Readout Expected in Q4 2024
Express News | Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, Melt-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
Belite Delights Investors, Soleno, ADMA, Harrow Deliver Triple-digit Gains, Keep An Eye On Oculis
Ophir Asset Management's Strategic Reduction in Harrow Inc Holdings
Harrow Is Maintained at Buy by Lake Street
The Analyst Landscape: 4 Takes On Harrow
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating, Announces Target Price $65
Lake Street Maintains Harrow(HROW.US) With Buy Rating, Raises Target Price to $55
Express News | Harrow, Inc. : Craig-Hallum Raises Target Price to $65 From $45
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains?
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
Harrow Relaunches FDA-approved Triesence, Shares Climb
Harrow, Inc. (HROW): A Bull Case Theory
Express News | Harrow Inc: Expansion to Create Nearly 150 New Jobs in Nashville
Harrow Announces Nashville Expansion